Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
Abstract
Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity of the kinases that participate in this pathway. Although promising, the efficacy of these therapies is short lived due to undesired toxicity and/or drug resistance problems. As an alternative path, new efforts are now being devoted to the targeting of protein-protein interactions (PPIs) involved in the flow of RAS-ERK signals. Many of these efforts have shown promising results in preclinical models. In this review, we summarize recent progress made in this area.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ROS-induced dysfunction in the Ras-ERK pathway appears to be a major cause of the incidence of many cancers.
“ROS-induced dysfunction in the Ras-ERK pathway appears to be a major cause of the incidence of many cancers (García-Gómez et al. 2018).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as García-Gómez et al. 2018
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works
Hauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,974 · see citing works
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,698 · see citing works
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,916 · see citing works
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,837 · see citing works
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,642 · see citing works
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,317 · see citing works
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · see citing works
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676 · see citing works
Regulation of Raf-1 by direct feedback phosphorylation.
Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663 · see citing works
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · see citing works
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618 · see citing works
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585 · see citing works
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562 · see citing works
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P. G., Moy, C. H., Szabo, S. A., Roadcap, L., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 545 · see citing works
Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543 · see citing works
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535 · see citing works
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · see citing works
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · see citing works
Sullivan, R. J., Infante, J. R., Jankú, F., Wong, D. J. L., Sosman, J. A., Keedy, V. L., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 437 · see citing works
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · see citing works
Infante, J. R., Somer, B. G., Park, J. O., Li, C., Scheulen, M. E., Kasubhai, S. M., Oh, D., Liu, Y., Redhu, S., Steplewski, K. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 365 · see citing works
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322 · see citing works
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317 · see citing works
Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 297 · see citing works
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293 · see citing works
Current Development Status of MEK Inhibitors
Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291 · see citing works
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Divakar, S. K. A., Carpio, R. V., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L. A., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 278 · see citing works
Identification and Characterization of a General Nuclear Translocation Signal in Signaling Proteins
Chuderland, D., Konson, A., & Seger, R. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.007 · Cited by 259 · see citing works
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Sturm, O. E., Orton, R. J., Grindlay, J., Birtwistle, M. R., Vyshemirsky, V., Gilbert, D., Muffy Calder, A., Pitt, A. R., Kholodenko, B. Ν., & Kölch, W. (2010) · Science Signaling · doi:10.1126/scisignal.2001212 · Cited by 248 · see citing works
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 239 · see citing works
Small-molecule modulation of Ras signaling
Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N., & Waldmann, H. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1560 · Cited by 215 · see citing works
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C. L., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R. H., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 212 · see citing works
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Freeman, A. K., Ritt, D. A., & Morrison, D. K. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.018 · Cited by 201 · see citing works
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors
Jameson, K., Mazur, P., Zehnder, A., Zhang, J.-J., Zarnegar, B., Sage, J., & Khavari, P. (2013) · Nature Medicine · doi:10.1038/nm.3165 · Cited by 200 · see citing works
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
Fritsche‐Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S. L., Brummer, T., Sers, C., & Blüthgen, N. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.27 · Cited by 193 · see citing works
Between a rock and a hard place?
Whitty, A., & Kumaravel, G. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0306-112 · Cited by 170 · see citing works
Identification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín‐Gago, P., Kovačević, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K. F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 164 · see citing works
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Thevakumaran, N., Lavoie, H., Critton, D., Tebben, A. J., Marinier, A., Sicheri, F., & Therrien, M. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2924 · Cited by 162 · see citing works
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 161 · see citing works
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Leshchiner, E. S., Parkhitko, A. A., Bird, G. H., Luccarelli, J., Bellairs, J. A., Escudero, S., Opoku-Nsiah, K., Godes, M., Perrimon, N., & Walensky, L. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413185112 · Cited by 159 · see citing works
The developing story of Sprouty and cancer
Masoumi-Moghaddam, S., Amini, A., & Morris, D. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9497-1 · Cited by 155 · see citing works
Casar, B., Pinto, A., & Crespo, P. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.024 · Cited by 152 · see citing works
Self-citationSmall Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Herrero, A., Pinto, A., Colón‐Bolea, P., Casar, B., Jones, M., Agudo‐Ibáñez, L., Vidal, R., Tenbaum, S. P., Nuciforo, P. G., Valdizán, E. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.001 · Cited by 148 · see citing works
Self-citationStructural Basis for Conformational Dynamics of GTP-bound Ras Protein
Shima, F., Ijiri, Y., Muraoka, S., Liao, J., Ye, M., Araki, M., Matsumoto, K., Yamamoto, N., Sugimoto, T., Yoshikawa, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125161 · Cited by 148 · see citing works
Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function
Hocker, H. J., Cho, K.-J., Chen, C.-Y. K., Rambahal, N., Sagineedu, S. R., Shaari, K., Stanslas, J., Hancock, J. F., & Gorfe, A. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300016110 · Cited by 144 · see citing works
The nuclear translocation of ERK1/2 as an anticancer target
Plotnikov, A. N., Flores, K., Maik-Rachline, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms7685 · Cited by 142 · see citing works
Eblen, S. T., Slack‐Davis, J. K., Tarcsafalvi, A., Parsons, J. T., Weber, M. J., & Catling, A. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2308-2317.2004 · Cited by 139 · see citing works
Sulindac sulfide inhibits Ras signaling
Herrmann, C., Block, C., Geisen, C., Haas, K., Weber, C. K., Winde, G., Möröy, T., & Müller, O. (1998) · Oncogene · doi:10.1038/sj.onc.1202085 · Cited by 129 · see citing works
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 125 · see citing works
Targeting RAS-mutant cancers: is ERK the key?
Ryan, M. B., Der, C., Wang-Gillam, A., & Cox, A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 125 · see citing works
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 125 · see citing works
Taveras, A. G., Remiszewski, S., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P. T., Pramanik, B. N., Snow, M. E., Wang, Y.-S., del Rosario, J., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00202-7 · Cited by 123 · see citing works
Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119 · see citing works
Identification of Novel Extracellular Signal-Regulated Kinase Docking Domain Inhibitors
Hancock, C. N., Macias, A. T., Lee, E. K., Yu, S. Y., MacKerell, A. D., & Shapiro, P. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501174 · Cited by 117 · see citing works
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 116 · see citing works
Qian, X., Esteban, L., Vass, W. C., Upadhyaya, C. D., Papageorge, A. G., Yienger, K., Ward, J. M., Lowy, D. R., & Santos, E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.642 · Cited by 116 · see citing works
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 112 · see citing works
Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos.
Buday, L., Ph, W., & Downward, J. (1995) · PubMed · Cited by 106 · see citing works
Wong, D., Robert, L., Atefi, M., Lassen, A., Avarappatt, G., Cerniglia, M., Avramis, E. V., Tsoi, J., Foulad, D., Graeber, T., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-194 · Cited by 104 · see citing works
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 104 · see citing works
Jada, S. R., Matthews, C., Saad, M. S., Hamzah, A. S., Lajis, N. H., Stevens, M. F. G., & Stanslas, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.368 · Cited by 101 · see citing works
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
Dhawan, N. S., Scopton, A. P., & Dar, A. C. (2016) · Nature · doi:10.1038/nature19327 · Cited by 94 · see citing works
The importance of Raf dimerization in cell signaling
Freeman, A. K., Ritt, D. A., & Morrison, D. K. (2013) · Small GTPases · doi:10.4161/sgtp.26117 · Cited by 90 · see citing works
Waldmann, H., Karaguni, I., Carpintero, M., Gourzoulidou, E., Herrmann, C., Brockmann, C., Oschkinat, H., & Müller, O. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353089 · Cited by 83 · see citing works
The RAS–Effector Interaction as a Drug Target
Keeton, A. B., Salter, E. A., & Piazza, G. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0938 · Cited by 77 · see citing works
Identification of Potent Ras Signaling Inhibitors by Pathway‐Selective Phenotype‐Based Screening
Müller, O., Gourzoulidou, E., Carpintero, M., Karaguni, I., Langerak, A., Herrmann, C., Möröy, T., Klein‐Hitpaß, L., & Waldmann, H. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200352587 · Cited by 70 · see citing works
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Atefi, M., Titz, B., Avramis, E. V., Ng, C., Wong, D., Lassen, A., Cerniglia, M., Escuin-Ordinas, H., Foulad, D., Comin-Anduix, B., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0293-5 · Cited by 65 · see citing works
An engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64 · see citing works
Tanaka, T. U., & Rabbitts, T. H. (2010) · Oncogene · doi:10.1038/onc.2010.346 · Cited by 62 · see citing works
Chen, F., Hancock, C. N., Macias, A. T., Joh, J., Still, K., Zhong, S., MacKerell, A. D., & Shapiro, P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.038 · Cited by 62 · see citing works
Arozarena, I., Calvo, F., & Crespo, P. (2011) · Genes & Cancer · doi:10.1177/1947601911409213 · Cited by 52 · see citing works
Self-citationVertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
Rebecca, V. W., Alicea, G. M., Paraiso, K. H. T., Lawrence, H., Gibney, G., & Smalley, K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12303 · Cited by 50 · see citing works
Boston, S. R., Deshmukh, R. R., Strome, S. E., Priyakumar, U. D., MacKerell, A. D., & Shapiro, P. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-7 · Cited by 43 · see citing works
González‐Pérez, V., Reiner, D. J., Alan, J. K., Mitchell, C. E., Edwards, L. J., Khazak, V., Der, C. J., & Cox, A. D. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-2 · Cited by 42 · see citing works
Design, Synthesis and Biological Evaluation of Sugar‐Derived Ras Inhibitors
Peri, F., Airoldi, C., Colombo, S., Martegani, E., van Neuren, A. S., Stein, M., Marinzi, C., & Nicotra, F. (2005) · ChemBioChem · doi:10.1002/cbic.200400420 · Cited by 41 · see citing works
Samadani, R., Zhang, J., Brophy, A., Oashi, T., Priyakumar, U. D., Raman, E. P., John, F. J. S., Jung, K.-Y., Fletcher, S., Pozharski, E. V., et al. (2015) · Biochemical Journal · doi:10.1042/bj20131571 · Cited by 40 · see citing works
Lim, J., Kelley, E. H., Methot, J. L., Zhou, H., Petrocchi, A., Chen, H., Hill, S. E., Hinton, M. C., Hruza, A. W., Jung, J. O., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00708 · Cited by 40 · see citing works
Schöpel, M., Jockers, K. F. G., Düppe, P. M., Autzen, J., Potheraveedu, V. N., Ince, S., Yip, K. T., Heumann, R., Herrmann, C., Scherkenbeck, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401291q · Cited by 38 · see citing works
P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
Babagana, M., Johnson, S., Slabodkin, H., Bshara, W., Morrison, C., & Kandel, E. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22611 · Cited by 35 · see citing works
Jung, K., Samadani, R., Chauhan, J., Nevels, K. J., Yap, J. L., Zhang, J., Worlikar, S. A., Lanning, M. E., Chen, L., Ensey, M., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40199e · Cited by 30 · see citing works
Sacco, E., Metalli, D., Spinelli, M., Manzoni, R., Šamalíková, M., Grandori, R., Morrione, A., Traversa, S., Alberghina, L., & Vanoni, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.011 · Cited by 22 · see citing works
Arafeh, R., Flores, K., Keren‐Paz, A., Maik-Rachline, G., Gutkind, N. E., Rosenberg, S. A., Seger, R., & Samuels, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16558-0 · Cited by 18 · see citing works
New Avenue to Inhibit Ras Signaling
Bustelo, X. R. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.001 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · see citing works
- Authors
- García-Gómez, R., Bustelo, X. R., & Crespo, P.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad de Cantabria (ES)
- Corresponding author
- Crespo, Piero
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 4
- Issue
- 9
- Pages
- 616-633
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2885743684
- Cited by
- 72
- References
- 90
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 14 · 2022: 10 · 2021: 13 · 2020: 4 · 2019: 5 · 2018: 2
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in cancer (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- protein-protein interaction, Ras/ERK signaling, oncogenic Ras, ERK kinase, anticancer drug targets, kinase inhibitors, drug resistance, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, ras Proteins, MAP Kinase Signaling System, Extracellular Signal-Regulated MAP Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
